Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
High exposure to triclosan, an antibacterial agent commonly found in consumer products, is associated with low bone mineral density (BMD) and an increased risk of osteoporosis among women, suggests epidemiological data from the NHANES*.
Higher dietary salt intake appears to increase body mass index (BMI) and the prevalence of overweight or obesity in Japan, China, the UK and the US, according to a recent study.
The risk of diabetes mellitus is higher among postmenopausal women who develop primary breast cancer, reports a new study.
Zinc supplementation significantly lowers key glycaemic indicators, particularly fasting glucose (FG) in individuals with diabetes and in those who received an inorganic supplement, results of a systematic review and meta-analysis have shown.
Doing a single bout of walking before dinner has little to no benefits in terms of 24-hour glucose profiles, with the notable exception of a reduction in glucose during the activity itself, according to the results of the E-Paradigm* study.
Maternal height is implicated in the risk of gestational diabetes mellitus, such that women with short stature are at high risk, according to the results of a meta-analysis.
The glycated haemoglobin (HbA1c) test and oral glucose tolerance test (OGTT) appear to have low concordance for diagnosing prediabetes or diabetes in overweight or obese men and women, a recent study reports.
Special Reports
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.
Dapagliflozin 5 mg and 10 mg FC tab
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
Conference Reports
Using insulin degludec combined with liraglutide (IDegLira) as initial injectable therapy in patients with type 2 diabetes (T2D) who were uncontrolled on oral antidiabetic drugs significantly delays the need for treatment intensification compared with insulin glargine 100 U/mL (IGlar U100) alone, the DUAL VIII study shows.
_1_2_3_Square.JPG)
Cardiovascular (CV) outcomes were similar between the dipeptidyl peptidase 4 (DPP-4) inhibitor linagliptin and the sulfonylurea glimepiride in the CAROLINA* study of patients with early type 2 diabetes (T2D) and increased CV risk.
A 2-week course of the immunotherapy drug teplizumab delayed the onset of type 1 diabetes (T1D) in individuals at high risk for the condition, according to a phase II trial conducted by the TrialNet Study Group and presented at ADA 2019.
The iLet Bionic Pancreas System can effectively control blood glucose levels in adults with type 1 diabetes (T1D), according to data from the first human study of the device presented at ADA 2019.
Patients with youth-onset type 2 diabetes (T2D) are more likely to have an increased rate of cardiovascular (CV), kidney, eye, nerve, and pregnancy complications as they transition to early adulthood, according to the longest-running TODAY*2 study presented at ADA 2019.
Podcast: Dr Lawrence Leiter expounds on the renal benefits seen with dapagliflozin in DECLARE-TIMI 58
Slideshow: Highlights from the 79th Scientific Sessions of the American Diabetes Association
Multimedia
